Silmitasertib
Silmitasertib
Silmitasertib (pronunciation: sil-mi-ta-ser-tib) is a small molecule inhibitor that targets the CK2 (Casein Kinase 2) protein. It is currently being studied for its potential use in the treatment of various cancers, including cholangiocarcinoma and medulloblastoma.
Etymology
The name "Silmitasertib" is derived from the combination of the words "silmi", which is an arbitrary prefix, and "tasertib", a common suffix used in the naming of kinase inhibitors. The "tasertib" part of the name is derived from the word "sertib", which is a common suffix used in the naming of kinase inhibitors.
Usage
Silmitasertib is used in clinical trials to study its effectiveness in treating various types of cancers. It works by inhibiting the activity of the CK2 protein, which is often overexpressed in cancer cells. By inhibiting this protein, Silmitasertib can potentially slow down or stop the growth of cancer cells.
Related Terms
- Inhibitor: A substance that slows down or stops a chemical reaction.
- CK2 (Casein Kinase 2): A protein that is often overexpressed in cancer cells.
- Cholangiocarcinoma: A type of cancer that forms in the bile ducts.
- Medulloblastoma: A type of brain tumor that starts in the cerebellum, the lower back part of the brain.
External links
- Medical encyclopedia article on Silmitasertib
- Wikipedia's article - Silmitasertib
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski